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Immune thrombocytopenic purpura (ITP) is an autoimmune disease characterized by low platelet counts and may be responsible for mucocutaneous bleeding of variable severity. 1 ITP is usually chronic (>6 months) in adults and, after this time, the probability of spontaneous remission is low. Standard management is to initiate steroids, anti-Rh 0 (D) immune globulins and/or intravenous immunoglobulins (IVIg) for the more severe forms. [2] [3] [4] [5] The response rate is high but most often transient. That the spleen plays a major role in the removal of damaged platelets has long been known and, to date, splenectomy is still considered the 'gold standard' treatment in many countries for the management of chronic ITP with platelet counts <30x10 9 /L, especially when hemorrhagic complications are present. About two-thirds of chronic ITP patients who undergo splenectomy achieve lasting responses. 6 As suggested in the guidelines of the American Society of Hematology (ASH) 7 and the British Committee for Standards in Haematology (BCSH), 8 splenectomy should be considered the main second-line therapy for patients who fail to respond durably to first-line therapy, with persistent platelet counts <30x10 9 /L. However, increasing numbers of patients are reluctant to undergo splenectomy and physicians are hesitant to recommend it. 9, 10 In addition, the risk of overwhelming post-splenectomy infections, although rare, is not predictable and represents a major concern. [11] [12] [13] Moreover, some authors reported that, despite initial good responses to splenectomy, the risk of late relapse persists during long-term follow-up 14, 15 and severe morbidity resulting from surgery is associated with 11-30% postoperative complications requiring prolonged hospitalization or re-admission. 11, 16 For these reasons, an effective and safe alternative to splenectomy would improve management of chronic ITP.
Rituximab is a chimeric, humanized monoclonal antibody directed against the CD20 determinant on B cells. It was initially developed for the treatment of malignant lymphoma but has also been used in autoantibody-mediated disorders, such as rheumatoid arthritis, 17 systemic lupus erythematosus, 18 autoimmune hemolytic anemia, 19 or thrombotic Moreover, the short follow-up in some reports and the possible bias due to the retrospective design of most of the studies make it difficult to draw definitive conclusions regarding efficacy. Despite the lack of evidence-based data, rituximab is now commonly used to manage chronic refractory ITP in Europe and North America, and is increasingly proposed before splenectomy. Thus, the BCSH guidelines suggested that rituximab might be of value for patients who failed to respond to first-and second-line therapies. 8 Whether it could be an effective and safe splenectomy-avoiding strategy in adults with chronic ITP remains unresolved. 22 To assess rituximab efficacy and safety in nonsplenectomized adults with chronic ITP (duration ≥ 6 months), we conducted a prospective, multicenter, open-label, single-arm phase 2 trial using Fleming's single-stage design.
PATIENTS AND METHODS

Patients
Eight French Hematology and Internal Medicine Departments enrolled patients. 
Study design
Rituximab (375 mg/m 2 ; Roche France) was infused intravenously once weekly for 4 weeks.
Patients were vaccinated against Streptococcus pneumoniae and Haemophilus influenzae at least 2 weeks before the first rituximab administration. Before each infusion, patients were premedicated with paracetamol (1 g) and intravenous methylprednisolone (60 mg). All treatments active against ITP had to be stopped at least 2 weeks before the first rituximab infusion, except steroids, which could be maintained in patients with bleeding and/or platelet counts <20x10 9 /L. In the latter situation, steroids had to be stopped within 21 days following the first rituximab infusion. No other treatments potentially active against ITP were given to patients during the 2 years of follow-up.
Every patient's bleeding severity was assessed in at inclusion and during follow-up using a previously described standardized bleeding score.
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Response and toxicity criteria
The primary endpoint of the study was to assess the response rate to treatment 1 year after the first rituximab infusion. A good response was defined as a platelet count Secondary endpoints were: the response rate 2 years after the first rituximab infusion, according to the same criteria, and the number of splenectomies performed 1 and 2 years after the first rituximab infusion.
Toxicity and side effects were recorded on standardized case-report forms.
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Statistical methods
Fleming's single-stage design 25 An ancillary objective was to determine whether baseline characteristics were associated with good response at 1-year, using Wilcoxon's rank-sum test or Fisher's exact test. A multiple logistic-regression model with backward stepwise model selection was used to remove potential confounders. All variables achieving P < .20 in the previous analysis were considered in the multivariate model, and retained in the model at a threshold of P = .05.
Model results are expressed as odds ratios (OR) [95% CI].
The probability of a patient achieving and sustaining a good response during follow-up was estimated with its point-wise 95% CI using multi-state models. 26 Analysis was performed on an intent-to-treat basis: the data obtained from all patients included in the trial were analyzed, except those who withdrew their consent. Patients receiving other treatment with known effect on ITP were considered treatment failures, regardless of the reason why it was administered. Except for the primary analysis, in which a one-sided test at the 0.025 level was used, all other tests used were two-sided at a 0.05 level.
RESULTS
Patient characteristics
Among 65 patients assessed for eligibility, 3 were excluded: 1 who had already participated in another trial and 2 others because they did not fulfill the inclusion criteria. Two additional No patient was lost-to-follow-up. Table 1 summarizes the main patient characteristics. All the patients had previously received steroids and/or IVIg and >80% had responded transiently to those first-line therapies.
Twenty-one patients with a median platelet count of 15x10 9 /L were taking steroids because of bleeding at the time of the first rituximab infusion and in accordance with the protocol, they were discontinued for all of them within the following 3 weeks. Relationships between baseline characteristics and the response pattern at 1 year are detailed in Table 2 . A multivariate logistic-regression model for treatment failure showed that younger age was the only independent factor significantly predictive of a good response at 1 year 
Efficacy
DISCUSSION
This report describes, for the first time, the results of a phase 2 prospective trial designed to assess rituximab efficacy at 1 and 2 years, and safety with long-term follow-up obtained from a homogeneous nonsplenectomized adult population with chronic ITP. We chose to evaluate rituximab efficacy in a single-arm, phase 2 trial because its short-term efficacy had been reported to be 25-50% 21 but the long-term response in a homogeneous nonsplenectomized adult population had never been prospectively studied. Our objective was not to compare rituximab to splenectomy, because the expected response rate after splenectomy (~65%) 6 would surely be higher than that of rituximab. However, splenectomy may be associated with immediate morbidity, a long-term and unpredictable risk of fatal overwhelming sepsis, [11] [12] [13] and it has also been emphasized that the risk of long-term relapse post-splenectomy has been underestimated. 14, 15 Therefore, finding a safe alternative therapeutic option to splenectomy which could induced a long-term remission is still an unmet need for patients with severe chronic ITP.
We considered that >25% response rate 1 year after the first rituximab infusion would imply that the biologic may be used as a splenectomy-avoiding agent and that the observed responses reflected the impact of rituximab rather than the natural course of ITP. Indeed, only patients with chronic ITP (i.e., lasting ≥ 6 months) were included in our study and it had been shown that, for adult ITP, the likelihood of spontaneous remission after 6 months of follow-up 11 was very low. 28 The phase 2 design that we used cannot provide definitive answers and does not demonstrate that rituximab is the best splenectomy-avoiding option. However, its results certainly showed that rituximab was apparently safe and effective pre-splenectomy option that warrants consideration in routine practice for adults with chronic ITP. Indeed, after 2 years of follow-up, good responses persisted in 33% of the patients and 40% of the patients had treatment-free platelet counts ≥ 30x10 9 /L. Based on their large meta-analysis, Arnold et al. 21 found an overall response defined as a platelet count >50x10 9 /L in 62% of the patients and thrombocytopenia recurred in only 10% of them. However, the median follow-up had been only 9.5 months (IQR: 6; 21 months). Other recent studies that included splenectomized and nonsplenectomized ITP patients reported sustained responses in 35-67% with median followup 9-54 months long. [29] [30] [31] But Schweizer et al. 32 reported conflicting results, with only 2 longlasting remissions among 14 patients.
According to our multivariate analysis, only younger age was associated with a long-term good response. Patients with long-term good responses were more frequently females and had received fewer previous treatments but these differences did not reach statistical significance.
To date, although it has been suggested that women and younger patients might respond better, 21, 33 factors predictive of ITP response to rituximab have not yet been clearly established. The optimal timing of rituximab administration in ITP also remains a matter of debate, even though early administration might have a better disease-modifying effect. 29, 30, 34 Notably, an early response to rituximab (i.e., occurring within 2 weeks after the first infusion) had been found to be associated with a better long-term response. 35 We confirmed that finding, because 18 of our 21 patients who had recovered normal platelet counts within the 2 weeks following their first rituximab infusion, still had normal platelet counts at 1 year.
However, as reported by Stasi et al., 36 some patients had slow platelet-count rises, indicating
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We did not observe any life-threatening side effect and only 1 patient in our cohort developed a severe infection. All patients, except the 1 who was diagnosed with transient serum sickness after the first 2 infusions, received 4 infusions, in accordance with the study protocol. Severe infections have been reported after rituximab was given to treat autoimmune diseases but most of those patients were severely immunocompromised. 37, 38 The good safety profile and the rarity of infections observed in our study could be explained by the small number of therapies preceding rituximab. This observation suggests that rituximab is a safe treatment in nonsplenectomized ITP patients and argues for its early administration during the course of ITP before considering the use of cytotoxic agents. We also observed 8 severe events, particularly 4 cardiovascular complications and 2 cancers judged unrelated to rituximab, but because of the single-arm design of our study, we cannot be absolutely sure that one of those complications was not causally related. However, as in the general population, these events occurred mainly in patients >60 years. Moreover, no cancer or cardiovascular complications were reported in the meta-analysis by Arnold et al. 21 that included >300 patients or in concurrently published studies 29, 31, 32, 39 not included in that metaanalysis.
Our results demonstrated that, when administered before splenectomy, rituximab achieved 33% good responses after 2 years of follow-up. Moreover, compared to historical data, rituximab does not seem to lower the response rate to splenectomy should it be required later due to rituximab failure. Rituximab should therefore be considered a pre-splenectomy therapeutic approach, particularly for patients with chronic ITP who are at high risk of undergoing the surgery and/or who are reluctant to do so. For personal use only. on October 28, 2017. by guest www.bloodjournal.org From
